10 results about "Atropa belladonna" patented technology

The present invention relates to the technical field of production technology of traditional Chinese medicine compositions, and specifically to a pharmaceutical composition, a plaster, and its preparation method and application. The formula comprises 18 to 35 parts of Aconitum kusnezoffii, 18 to 35 parts of Rhizoma Aconiti Kusnezoffii, 35 to 65 parts of Radix Saposhnikoviae, 35 to 65 parts of Cortex Periplocae, 65 to 85 parts of Angelica dahurica, 18 to 35 parts of Cloves, 35 to 115 parts of Belladonna fluid extract powder, 15 to 40 parts of Rutaecarpa extract powder, and 25 to 45 parts of methyl salicylate. The composition is obtained through the research on reducing the formula of Musk Wind-Chasing and Pain-Relieving Plaster, reducing the raw materials of medicinal materials from more than 20 to nine, so that it can still achieve the ideal therapeutic effect, realize component optimization and medicinal material saving. By further adding Strychnos nux vomica or a transdermal auxiliary composition, the therapeutic effect can be further enhanced. The present technical solution can solve the technical problems of Musk Wind-Chasing and Pain-Relieving Plaster in the prior art, such as the complex processing technology and high production cost, caused by the complex raw material components, and has great prospects for promotion and application.

This invention discloses a method for refining and desalting belladonna fluid extract, relating to the field of traditional Chinese medicine pharmaceuticals. Belladonna grass is pulverized through a 24-mesh sieve to form coarse powder. The powder is percolated using ethanol as a solvent to obtain a primary belladonna extract. The ethanol is recovered from the primary extract, and the extract is cooled to room temperature. Chlorophyll is removed by separation using a ceramic membrane. The extract is then filtered, and the filtrate is concentrated using an organic nanofiltration membrane to remove salts. The membrane filtrate is further concentrated under reduced pressure to a thick paste. Seven times the volume of ethanol is added and stirred until homogeneous. The mixture is allowed to stand until complete precipitation. The supernatant is collected, and the ethanol is recovered and concentrated to a thick paste. Based on the content determined in the thick paste, an appropriate amount of 85% ethanol is added, and the mixture is diluted with water to prepare a finished belladonna fluid extract product conforming to pharmacopoeia standards. This method is stable and reliable, avoids high-temperature degradation of the active ingredients, effectively removes impurities from the belladonna fluid extract, and prevents salt precipitation in the finished product. This ensures its efficacy and medication safety, and has broad market application prospects.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition with the function of relieving stomach inflammation and a preparation method and application. The traditional Chinese medicine composition comprises a main medicine and an auxiliary medicine, the main medicine consists of cuttle bone, thunberg fritillary bulb and rheum officinale; the adjuvants comprise a first adjuvant and a second adjuvant; the first adjuvant is belladonna and daphniphyllum calycinum; the second adjuvant comprises fructus aurantii and cortex magnoliae officinalis. The traditional Chinese medicine composition provided by the invention is simple in component, only a trace amount of belladonna extract needs to be added, meanwhile, daphniphyllum calycinum is compounded, the addition of excessive other unnecessary components is avoided, and the symptom of chronic non-atrophic gastritis with erosion can be remarkably improved.

The invention relates to medicine, and more particularly to algology, and can be used in the treatment of pain. The present method includes oral administration of a pharmaceutical composition. Administration begins with a minimum single dose comprising: 1 drop or granule of the composition, dissolved in 15 ml of water, per 10 kg of the patient's weight. The minimum single dose is administered every 15 minutes. An individually tailored single dose is determined by adding up the minimum doses of the composition which induce a subjective sensation of a decrease in pain. The composition is administered in the individually tailored single dose at a dosage frequency of not more than 8 times a day on the first day and not more than four times a day on the second and subsequent days. The pharmaceutical composition contains equal quantities of Eupatorium perfoliatum in a 3D dilution, China officinalis, Secale comutum, Arnica montana in a 3C dilution, Rhus toxicodendron in a 4C dilution, Aconitum napellus, Belladonna, Bryonia alba, Ipecacuanha, Nux vomica in a 5C dilution, Mercurius solubilis in a 6C dilution, Abrotanum, Gallicum acidum, Heloderma suspectum, Senecio aureus in a 7C dilution, and Stramonium in a 9C dilution. The invention provides for a significant decrease in the pain sensations experienced by the patient, irrespective of the source of and reasons for the pain.

The invention discloses an application of an overexpressed AbMYB93 gene in enhancing the resistance of atropa belladonna to stem rot caused by fusarium, a fusarium strain is separated from a typical atropa belladonna diseased plant, and the fusarium strain can cause stem rot and finally cause death of the plant. Further research finds that the plant hormone brassinolide (BR) can enhance the resistance of the atropa belladonna to the pathogen and increase the TAs content at the same time. Afterwards, the invention reveals that the BR directly up-regulates the expression of a key biosynthetic gene of scopoletin through AbMYB93, so that the resistance of atropa belladonna to the pathogen is enhanced. In conclusion, the research results show that AbMYB93 is a novel regulatory factor for the disease resistance of atropa belladonna, and a practical method for solving the disease resistance of atropa belladonna is established.

This invention discloses the application of overexpression of transcription factor AbbHLH29 in improving the biological traits of belladonna. By overexpressing AbbHLH29 in belladonna, this invention increases the expression level of the H6H gene, iron content, chlorophyll a content, aboveground biomass, or the content of scopolamine and anisodamine. The nucleotide sequence of AbbHLH29 is shown in SEQ ID No. 11. This research is not only significant in elucidating the molecular mechanism by which AbbHLH29 regulates the biosynthesis of belladonna alkaloids and iron homeostasis, but also provides important technical support for future research on belladonna alkaloid metabolic engineering.

The invention discloses a phenyllactic acid UDP-glycosyl transferase mutant and application thereof, and belongs to the technical field of biological medicine, the phenyllactic acid UDP-glycosyl transferase mutant PLA-UGT-M5 with improved catalytic efficiency is obtained through a directed evolution method, the mutant simultaneously contains five amino acid substitutions F19S, G21E, N128S, I209L and I292V, metabolites are detected in yeast cells, and the activity of the metabolites is improved. The catalytic efficiency is obviously higher than that of a wild type. Further functional verification shows that the PLA-UGT-M5 can remarkably promote biosynthesis of the scopolamine and the scopolamine in a yeast cell factory and a belladonna hairy root system, has a good metabolic engineering application prospect, provides a key tool for efficient biosynthesis of the scopolamine and the scopolamine, and has important industrial application potential.

The invention relates to an enteric analgesic suppository for treating haemorrhoids and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine suppositories. The haemorrhoid relieving enteric-coated analgesic suppository is prepared from the following raw materials in parts by weight: 23 to 28 parts of vinegar-processed rhizoma corydalis, 23 to 28 parts of radix angelicae, 2 to 5 parts of borneol, 1 to 2 parts of belladonna extract, 3 to 6 parts of nefopam, 8 to 12 parts of diclofenac sodium, 0.5 to 1 part of meloxicam and 160 to 190 parts of matrix. The traditional Chinese medicines and the western medicines are reasonably configured by analyzing the mechanism of the medicine effect on nerves, the related nerves are influenced from different levels, the mechanism of generating local pain is inhibited or blocked from different angles and different levels, the synergistic analgesia is realized, the obvious analgesic and anti-inflammatory effects are realized, the obvious stimulation to local tissues is avoided, and the safety is good. The suppository analgesic can directly introduce the medicine into an action target position to play a local effect, so that the influence of the medicine on the whole body is reduced.

The invention discloses a sesame bacterial wilt prevention and treatment agent and a prevention and treatment method, and belongs to the technical field of plant protection. The sesame bacterial wilt prevention and treatment agent comprises the following raw materials in parts by mass: 1.5-2 parts of a microbial compound, 1-2 parts of a plant extract, 15-20 parts of a straw fermentation product, 15-20 parts of biomass charcoal, 20-25 parts of peanut shells and 2-3 parts of hydroxypropyl methyl cellulose, wherein the plant extract comprises the following components in parts by mass: 6-9 parts of a nightshade / belladonna mixed extract and 10-12 parts of a purslane extract. The sesame bacterial wilt prevention and control agent has an excellent disease prevention and control effect, and the yield of sesame can be increased while diseases are prevented and controlled.

The application discloses a phenyllactic acid UDP-glycosyltransferase mutant and application thereof, and belongs to the technical field of biological medicine. A phenyllactic acid UDP-glycosyltransferase mutant PLA-UGT-M5 with improved catalytic efficiency is obtained through a directed evolution method. The mutant simultaneously contains five amino acid substitutions F19S, G21E, N128S, I209L and I292V. Metabolic products are detected in yeast cells, and the mutant shows a catalytic efficiency significantly higher than that of a wild type. Further functional verification shows that the PLA-UGT-M5 can significantly promote the biosynthesis of scopolamine and hyoscyamine in a yeast cell factory and a belladonna hairy root system, has a good metabolic engineering application prospect, provides a key tool for the efficient biosynthesis of scopolamine and hyoscyamine, and has important industrial application potential.